Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Ronald S Go,Amie Fonder,Mrinal M Patnaik,Yi Lin,Beth Brunton,Marissa Giers,Rahma Warsame ,Joselle Cook,Prashant Kapoor,Martha Q Lacy,Santosh Kumar ,David Dingli,Francis K Buadi,P Leif Bergsagel,Stephen J Russell,Thomas E Witzig,Nandakumar Packiriswamy,Stephen M Broski ,Taxiarchis Kourelis,Amylou C Dueck,Miriam Hobbs ,Morie A Gertz ,Wilson I Gonsalves ,Nelson Leung,Angela Dispenzieri,Brenda Ginos ,Robert A Kyle,Mustaqeem Siddiqui ,John A Lust,Yi L Hwa,Kah-Whye Peng ,Suzanne R Hayman,Eli Muchtar,S Vincent Rajkumar

doi:10.1182/blood-2020-140853

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Ronald S Go, Amie Fonder + Show 32 more

Open Access

https://doi.org/10.1182/blood-2020-140853

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 1

Affiliation: Mayo Clinic, Winneshiek Medical Center, Mayo Clinic Health System

#Research Funding #Hematologic Adverse Events + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL)

Full Text